Poxel : Corporate Presentation

Corporate Presentation

June 2023

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may",

"will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These

statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

2

Poxel's Mission & Key Investment Highlights

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC INFLAMMATION

DISORDERS

(cellular energy

homeostasisTISSUE

imbalances) DEGENERATION & CELL DEATH

apoptosis,

necrosis

Strategic focus on rare metabolic diseases and NASH

Royalties from TWYMEEG® (Imeglimin), approved and launched in Japan in 2021 for Type 2 Diabetes

Proven capabilities to build solid partnerships and to lead drug development

Highly Experienced Management Team in

Metabolic Diseases

3

Key Financial & Shareholder Information

Market data	Shareholder ownership1

Bpi France

14.4%

Ticker: POXEL

ISIN: FR0012432516

Number of shares: 31 764 6561

Key financials

• As of 3/31/23 cash & cash equivalents:
  EUR 10.6 million

Founders

8.8%

Floating

76.8%

Analyst coverage

Bryan Garnier	Alex Cogut
Degroof Petercam	David Seynnaeve
Jefferies	Lucy Codrington
JMP Securities	Jason Butler
Oddo	Martial Descoutures

4 1. As of April 30, 2023. For the most up to date share count, please refer to the website: Regulatory Documentation | Poxel SA (poxelpharma.com)

Leadership Team

Highly Experienced Management Team; Extensive R&D and Metabolic Expertise

Thomas Kuhn (Pharm D,
MBA)		Pascale Fouqueray (MD, PhD)
Chief Executive Officer and
	EVP, Clinical Development &
Co-founder
Sébastien Bolze (Pharm D,	Regulatory Affairs,
	PhD)	Co-founder
	EVP, Chief Operating Officer
	(COO), Co-founder

Sophie Bozec (PhD)

SVP, R&D Pharmacology &

Scientific Communication,	Quentin Durand
Co-founder	EVP, Chief Legal Officer and

	Head of CSR Corporate
	Social Responsibility
Based in the US
Elizabeth Woo
SVP, Investor Relations, Public	Sylvie Bertrand
Relations & Corporate	Vice President, Human
Communications
Resources

5